Brief Title
Procalcitonin-Guided Antibiotic Therapy in Bronchiectasis
Official Title
Effectiveness of Procalcitonin-Guided Antibiotic Therapy in Acute Exacerbations of Bronchiectasis: a Randomized Controlled Trial
Brief Summary
To explore effectiveness of procalcitonin-guided antibiotic therapy in acute exacerbations of bronchiectasis, and to explore the clinical value of procalcitonin in bronchiectasis.
Study Type
Interventional
Primary Outcome
Antimicrobial prescription rate
Secondary Outcome
Effective rate of clinical treatment
Condition
Procalcitonin
Intervention
Procalcitonin
Study Arms / Comparison Groups
Procalcitonin-guided antibiotic treatment group
Description: Patients were divided into 2 subgroups: No infection group (including patients with procalcitonin<0.1 ng/ml at enrollment, and patients with 0.1 ng/ml ≤procalcitonin ≤0.25 ng/ml at enrollment who are with stable respiratory and hemodynamics, and without serious complications) : the group is not given the application of antibiotics. Infection group (including patients with procalcitonin>0.25 ng/ml at the time of enrollment, and patients with 0.1 ng/ml ≤ procalcitonin≤0.25 ng/ml at enrollment who have severe disease, unstable hemodynamics, and severe complications or intensive care unit treatment): the group is given the application of antibiotics. According to the guidelines for severe sepsis / septic shock treatment, the standard for discontinuation of antimicrobial agents: If the procalcitonin level falls below <0.1 ng/ml or more than 80%, compared with the baseline before enrollment, it is recommended to discontinue the antimicrobial agent.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Other
Estimated Enrollment
210
Start Date
January 1, 2014
Completion Date
February 1, 2017
Primary Completion Date
July 1, 2016
Eligibility Criteria
Inclusion Criteria: 1. Bronchiectasis was diagnosed by high-resolution computed tomography based on the criteria published by McShane PJ et al. 2. Acute exacerbations of bronchiectasis. 3. Aged >= 18 years. 4. Procalcitonin been detected after admission. Exclusion Criteria: 1. Associated with chronic obstructive pulmonary disease. 2. Associated with asthma. 3. Traction bronchiectasis caused by pulmonary fibrosis. 4. Rule out other possible cause procalcitonin increased diseases such as cancer, connective tissue disease, active tuberculosis, chronic liver disease and respiratory system than the bacterial infection. 5. Clinical data were incomplete. 6. Can not follow up with the person.
Gender
Female
Ages
18 Years - 80 Years
Accepts Healthy Volunteers
No
Contacts
, ,
Administrative Informations
NCT ID
NCT03058718
Organization ID
lwsrmyy
Responsible Party
Principal Investigator
Study Sponsor
Qilu Hospital of Shandong University
Study Sponsor
, ,
Verification Date
February 2017